WOLFGANG SCHAEFER,JOERG THOMAS REGULA,LAURENT LARIVIERE,SABINE IMHOF-JUNG,SEBASTIAN FENN,PETRA RUEGER,MICHAEL MOLHOJ,CHRISTIAN KLEIN,ULRICH GOEPFERT,HARALD DUERR
申请号：
ARP160102974
公开号：
AR106189A1
申请日:
2016.09.29
申请国别(地区):
AR
年份:
2017
代理人:
摘要：
Double antibodies against human A-B / human transfer recipient and method of use are provided here. Claim 1: a double antibody consisting of (a) two antibodies, each consisting of a short chain antibody and a long chain antibody, In these long and short chains, each couple's junction points are specifically connected to the first antigen, (b) additional magic fragment, which merges with the C-terminal of one of the long antigen chains,In the second antigen, each short chain antibody contains the rest of the amino acid argon (not other wild glutamic acid) at position 123 in the continuous short chain long domain (CL)； At 124th, the rest of the amino acid lysine (rather than other wild glutamate； mutant q124k) (according to Kabat number)Each long chain antibody contains 147 other glucuronides (not other wild lysine； mutant k147e) in the first constant long chain domain (ch1), and 213 contain residual glucuronides (not other wild lysine)； Mutacion k213e (according to Kabat EU index number)In addition, Fab fragments, especially the binding with the second antigen, contain domain crossing. Therefore, sustained short chain control (CL) and sustained long chain control (ch1) are mutually substituted. The first antigen is human protein, and the second antigen is an antigen Human body transfer receiver. Claim 10: antibodies in any one of the 1 to 7 claims for the treatment of Alzheimer's disease.Se proporcionan aquí anticuerpos biespecíficos anti-A-b humana / receptor de transferrina humano y métodos de uso de los mismos. Reivindicación 1: Un anticuerpo biespecífico formado por: a) un anticuerpo que contiene dos parejas, cada una de una cadena corta de anticuerpo y una cadena larga de anticuerpo, en el que los sitios de unión formados por cada una de las parejas de la cadena larga y la cadena corta se unen específicamente al primer antígeno y b) un fragmento Fab adicional, dicho fragmento Fab adicional está fusionado con el extremo C de una de las cadenas largas del anticu
